VANCOUVER, British Columbia, Jun 07, 2007 -- As a follow up to ProtoKinetix Inc.'s (OTCBB:PKTX) May 23, 2007 press release related to cryopreserved (or frozen) cells treated with AAGP(TM), in collaboration with the University of Helsinki, Finland, ProtoKinetix has recently finished a set of trials designed to determine whether AAGP(TM) treated cells could survive after preservation in refrigeration (4 degrees C). Commenting on the results, ProtoKinetix's Director of Scientific Affairs, Dr. John Todd, stated, "After 3 days of preservation in refrigeration, untreated stem cells have a very high mortality rate. In the most recent experiments with the University of Helsinki, Finland, it was determined that AAGP(TM) can significantly reduce this cell death rate. AAGP(TM) demonstrated an impressive and repetitive 8 to 12 times increase in cell viability and survivability." Dr. Todd added, "These results are extremely important and encouraging for isolating the limited stem cell populations found in certain organs and tissues, such as umbilical cord blood and bone marrow. The implications for the treatment of certain types of cancers, such as leukemia and other conditions requiring bone marrow transplant are enormous." For further information, investors are asked to visit the ProtoKinetix Investor Relations Hub at www.agoracom.com/IR/ProtoKinetix or email to PKTX@agoracom.com. About ProtoKinetix: ProtoKinetix Inc. is a Biotechnical Company dedicated to the development of a family of synthetic antifreeze glycoproteins (AAGP(TM)) for human and veterinary medicine, the biotechnology and cosmetic industries. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world recognized intellectual talent in a networked environment, PKTX is conducting rapid and meaningful research with a view to developing markets for this very useful family of molecules. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission at www.sec.gov. On behalf of the Board of Directors Company Office: Suite # 1500 885 West Georgia Street Vancouver, BC V6C 3E8 ProtoKinetix Inc. Blair Henderson, 604-687-9887